NASDAQ:OSUR

OraSure Technologies - OSUR Stock Forecast, Price & News

$3.66

+0.07 (+1.95%)

(As of 09/23/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.45
▼
$3.68
50-Day Range: $2.90
▼
$4.61
52-Week Range: $2.62
▼
$11.89

Volume: 802,842 shs
Average Volume: 730,570 shs
Market Capitalization: $265.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

OraSure Technologies MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 227.9% Upside
$12.00 Price Target
Short Interest: Healthy
4.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.09
Upright™ Environmental Score
News Sentiment: 1.22
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$263,538 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.67) to ($0.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.84 out of 5 stars

Medical Sector

56th out of 1,080 stocks

Surgical & Medical Instruments Industry

6th out of 104 stocks

3.5

Analyst's Opinion

Consensus Rating
OraSure Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, OraSure Technologies has a forecasted upside of 227.9% from its current price of $3.66.
Amount of Analyst Coverage
OraSure Technologies has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
4.57% of the float of OraSure Technologies has been sold short.
Short Interest Ratio / Days to Cover
OraSure Technologies has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in OraSure Technologies has recently decreased by 5.37%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
OraSure Technologies does not currently pay a dividend.
Dividend Growth
OraSure Technologies does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
OraSure Technologies has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Respiratory tract infection tests" products. See details.
Environmental Sustainability
The Environmental Impact score for OraSure Technologies is -1.09.

2.9

News and Social Media Coverage

News Sentiment
OraSure Technologies has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for OraSure Technologies this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OraSure Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $263,538.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.20% of the stock of OraSure Technologies is held by insiders.
Percentage Held by Institutions
90.20% of the stock of OraSure Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for OraSure Technologies are expected to grow in the coming year, from ($0.67) to ($0.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OraSure Technologies is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OraSure Technologies is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OraSure Technologies has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OraSure Technologies (NASDAQ:OSUR) Stock

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

Receive OSUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OraSure Technologies and its competitors with MarketBeat's FREE daily newsletter.

OSUR Stock News Headlines

September 21, 2022 | apnews.com

OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored ...

September 20, 2022 | benzinga.com

OraSure Wins Contract to Supply "Together Take Me Home," HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

September 20, 2022 | nz.finance.yahoo.com

OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

September 20, 2022 | finance.yahoo.com

OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

September 14, 2022 | finance.yahoo.com

OraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health

September 14, 2022 | finance.yahoo.com

OraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health

August 31, 2022 | finance.yahoo.com

Independent Director Ronny Lancaster Just Bought 91% More Shares In OraSure Technologies, Inc. (NASDAQ:OSUR)

August 30, 2022 | nasdaq.com

Great news for OraSure Technologies, Inc. (NASDAQ:OSUR): Insiders acquired stock in large numbers last year

August 14, 2022 | finance.yahoo.com

Analysts Just Published A Bright New Outlook For OraSure Technologies, Inc.'s (NASDAQ:OSUR)

August 10, 2022 | seekingalpha.com

OraSure adds 25% as COVID-19 testing drives Q2 earnings beat

August 9, 2022 | finance.yahoo.com

OraSure Technologies (OSUR) Reports Break-Even Earnings for Q2

August 9, 2022 | finance.yahoo.com

OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year

August 2, 2022 | finance.yahoo.com

OraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET

July 28, 2022 | benzinga.com

OraSure's Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack

July 28, 2022 | finance.yahoo.com

OraSure’s Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack

July 14, 2022 | finance.yahoo.com

OraSure Technologies (NASDAQ:OSUR) shareholders have endured a 84% loss from investing in the stock five years ago

June 14, 2022 | finance.yahoo.com

Does This Valuation Of OraSure Technologies, Inc. (NASDAQ:OSUR) Imply Investors Are Overpaying?

June 8, 2022 | finance.yahoo.com

OraSure Technologies Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 26, 2022 | nasdaq.com

OraSure Technologies Now the Least Expensive vs. Binance Coin This Year

May 25, 2022 | seekingalpha.com

OraSure gains as U.S. selects COVID-19 rapid test for school distribution

May 25, 2022 | finance.yahoo.com

InteliSwab® COVID-19 Rapid Test Selected by Federal Government for Nationwide School Testing

May 23, 2022 | seekingalpha.com

OraSure Technologies gets new CEO

May 23, 2022 | finance.yahoo.com

Carrie Eglinton Manner Appointed Chief Executive Officer of OraSure

May 17, 2022 | finance.yahoo.com

InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants

May 10, 2022 | investing.com

OraSure Technologies Misses Q1 EPS by 19c

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OSUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OraSure Technologies and its competitors with MarketBeat's FREE daily newsletter.

OSUR Company Calendar

Last Earnings: 8/09/2022
Today: 9/24/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:OSUR
CUSIP: 68554V10
CIK: 1116463
Web: www.orasure.com
Phone: (610) 882-1820
Fax: 610-882-1830
Employees: 785
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.00
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +227.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,000,000.00
Net Margins: -24.18%
Pretax Margin: -21.79%
Return on Equity: -12.92%
Return on Assets: -10.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.08
Quick Ratio: 2.99

Sales & Book Value

Annual Sales: $233.67 million
Price / Sales: 1.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.28 per share
Price / Book: 0.69

Miscellaneous

Outstanding Shares: 72,620,000
Free Float: 71,021,000
Market Cap: $265.79 million
Optionable: Optionable
Beta: -0.03

Key Executives

Mr. Scott Gleason (Age 43)
Sr. VP of Investor Relations & Corp. Communications
Comp: $362.92k

Ms. Kathleen Gallagher Weber (Age 54)
Pres of Molecular Solutions
Comp: $1.12M

Ms. Carrie Eglinton Manner (Age 47)
Pres, CEO & Director

Mr. Kenneth J. McGrath
Chief Financial Officer

Ms. Michele Marie Miller (Age 48)
Sr. VP, Chief Accounting Officer, Controller & Assistant Sec.

Mr. David A. Rappaport C.F.A.
CFA, Sr. VP Corp. Devel., Strategy & Integration

Amy Steigerwalt
VP of HR

Ms. Lisa Nibauer (Age 53)
Pres of Diagnostics

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OSUR Stock - Frequently Asked Questions

Should I buy or sell OraSure Technologies stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OSUR shares.
View OSUR analyst ratings or view top-rated stocks.
What is OraSure Technologies' stock price forecast for 2022?: 2 analysts have issued 1 year price objectives for OraSure Technologies' shares. Their OSUR share price forecasts range from $10.00 to $14.00. On average, they predict the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 227.9% from the stock's current price.
View analysts price targets for OSUR or view top-rated stocks among Wall Street analysts.
How have OSUR shares performed in 2022?: OraSure Technologies' stock was trading at $8.69 at the start of the year. Since then, OSUR shares have decreased by 57.9% and is now trading at $3.66.
View the best growth stocks for 2022 here.
When is OraSure Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our OSUR earnings forecast.
How were OraSure Technologies' earnings last quarter?: OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.12. The medical instruments supplier earned $80.23 million during the quarter, compared to analyst estimates of $69.91 million. OraSure Technologies had a negative net margin of 24.18% and a negative trailing twelve-month return on equity of 12.92%. OraSure Technologies's quarterly revenue was up 39.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) earnings per share.
What guidance has OraSure Technologies issued on next quarter's earnings?: OraSure Technologies issued an update on its third quarter 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $90.00 million-$95.00 million, compared to the consensus revenue estimate of $76.15 million.

What is Stephen Tang's approval rating as OraSure Technologies' CEO?: 2 employees have rated OraSure Technologies Chief Executive Officer Stephen Tang on Glassdoor.com. Stephen Tang has an approval rating of 100% among the company's employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of OraSure Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), Overstock.com (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).
What is OraSure Technologies' stock symbol?: OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."
Who are OraSure Technologies' major shareholders?: OraSure Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (4.74%), Renaissance Technologies LLC (3.32%), Kennedy Capital Management Inc. (1.55%), Primecap Management Co. CA (1.26%), Wells Fargo & Company MN (1.20%) and Northern Trust Corp (1.05%). Insiders that own company stock include Michael Celano, Nancy J Gagliano and Ronny B Lancaster.
View institutional ownership trends.
How do I buy shares of OraSure Technologies?: Shares of OSUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is OraSure Technologies' stock price today?: One share of OSUR stock can currently be purchased for approximately $3.66.
How much money does OraSure Technologies make?: OraSure Technologies (NASDAQ:OSUR) has a market capitalization of $265.79 million and generates $233.67 million in revenue each year. The medical instruments supplier earns $-23,000,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.
How many employees does OraSure Technologies have?: The company employs 785 workers across the globe.
How can I contact OraSure Technologies?: OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The official website for the company is www.orasure.com. The medical instruments supplier can be reached via phone at (610) 882-1820, via email at investorinfo@orasure.com, or via fax at 610-882-1830.

This page (NASDAQ:OSUR) was last updated on 9/24/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

OraSure Technologies - OSUR Stock Forecast, Price & News

OraSure Technologies MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month